Background:
Gastric cancer(GC) is currently one of the major malignancies that threatens human lives and
health. Anlotinib is a novel small-molecule that inhibits angiogenesis to exert anti-tumor effects. However, the function in
gastric cancer is incompletely understood.
Objective:
The aim of the present study was to investigate the anti-tumor effects and molecular mechanisms of anlotinib
combined with dihydroartemisinin (DHA) in SGC7901 gastric cancer cells.
Method:
Different concentrations of anlotinib and DHA were used to treat SGC7901 gastric cancer cells, after which cell
proliferation was measured. Drug interactions of anlotinib and DHA were analyzed by the Chou-Talalay method with CompuSyn software. proliferation, apoptosis, invasion, migration, and angiogenesis were measured using the cell counting kit-8
(CCK8) assay, flow cytometry, Transwell invasion assays, scratch assays, and chicken chorioallantoic membrane (CAM)
assays. proliferation-associated protein (Ki67), apoptosis-related protein (Bcl-2), and vascular endothelial growth factor A
(VEGF-A) were quantified by Western bloting.
Results:
The combination of 2.5 μmol/L of anlotinib and 5 of μmol/L DHA was highly synergistic in inhibiting cell growth,
significantly increased the apoptosis rate and suppressed obviously the invasion and migration capability and angiogenesis
of gastric cancer cells. In addition, the expression levels of Ki67, Bcl-2, and VEGF-A, as well as angiogenesis, were significantly decreased in the Combination of drugs compared with in control and either drug alone.
Conclusion:
The combination of anlotinib and DHA showed synergistic antitumor activity, suggesting their potential in
treating patients with gastric cancer.
KLF11 promotes gastric cancer invasion and migration by increasing Twist1 expression
